U.S. Diversified Financial Stock News

Why Carlisle Companies is on investors’ radar today Carlisle Companies (CSL) is drawing attention after recent share price moves, with the stock showing a mix of modest gains over the past week alongside weaker performance over the past month and past 3 months. Those shifts are prompting closer scrutiny of its US$13.5b market value, current price near US$331, and broader context as a building envelope products manufacturer with operations across the United States, Europe and other...

Timken: key performance markers investors are watching Timken (TKR) has drawn fresh attention after recent share moves, with the stock showing mixed returns over the past week, month and past 3 months while longer term performance and profitability metrics present a different picture. See our latest analysis for Timken. At a share price of $98.94, Timken’s recent 7 day share price return of 3.13% contrasts with a modest 30 day share price pullback, while the 1 year total shareholder return of...

Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site. See our latest analysis for Scholar Rock Holding. The BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum...

In recent months, Ormat Technologies has outlined plans to add 149 MW of new capacity by the end of 2027, including 101 MW from geothermal projects, while committing US$180 million to build additional energy storage assets in the United States through 2028. This combination of geothermal expansion and sizable storage investment highlights Ormat’s effort to deepen its role in supplying grid-stable renewable power as adoption of clean energy accelerates. Next, we’ll explore how Ormat’s planned...

Why CNA Financial (CNA) Is Back in Focus After Its Latest Quarter CNA Financial (CNA) has drawn fresh attention after quarterly results came in below market expectations, with weaker core earnings per share and profitability despite growth in premiums and investment income. At the same time, management raised the regular dividend by 4% and announced a special dividend. This move highlights confidence in ongoing cash generation, even as underwriting performance and higher expenses remain key...

In recent weeks, Meta Platforms has faced major legal setbacks as US juries in California and New Mexico found its social media products liable for addictive design harms to minors, resulting in multimillion‑dollar penalties and fresh scrutiny of its platform practices. These rulings mark one of the first times a large social network has been treated as a potentially defective product under US product liability law, opening the door to broader challenges against how Meta engineers engagement...

Why AXT’s share authorization move matters for investors AXT (AXTI) is back in focus after proposing a sizable increase in authorized common shares, from 70,000,000 to 120,000,000, ahead of its May 14, 2026 annual stockholder meeting. See our latest analysis for AXT. The latest share authorization proposal comes after a sharp pullback, with a 1 day share price return of negative 20.53%, a 90 day share price return of 108.18%, and a 1 year total shareholder return that is very large. Recent...

OSI Systems recently announced that its Optoelectronics and Manufacturing division secured a multi-year contract worth more than US$40,000,000 from a leading medical device OEM to supply critical electronic sub-assemblies for medical platforms. This award highlights OSI Systems' manufacturing capabilities in high-reliability healthcare components and deepens its presence in medical device supply chains, adding another long-duration program to its backlog. Next, we’ll examine how this...

In the fourth quarter of 2025, Medpace Holdings reported a 32% year-over-year revenue increase, while Mairs & Power Small Cap Fund cited the company as a key contributor in its investor letter due to stronger clinical trial trends linked to GLP-1 programs. This combination of healthier trial cancellation patterns and momentum in GLP-1 research highlights how Medpace is benefiting from current demand in metabolic-related clinical development. We’ll now explore how this improved GLP-1-driven...

On March 24, 2026, Ardent Health, Inc. announced that Ethan Chernin departed the company and would no longer serve as President, Hospital Services, with his separation treated as a “Qualifying Termination” under the firm’s Executive Severance Plan. This leadership change in a core operating role raises important questions about continuity in hospital operations and the company’s broader execution plans. We’ll now examine how the sudden exit of Ardent’s President of Hospital Services may...

Macy's (M) shares recently closed at US$18.13, drawing renewed attention to how investors view this long established omni channel retailer along with its current valuation, recent returns, and underlying business trends. See our latest analysis for Macy's. Recent trading has been mixed, with a 1 day share price return of 1.74% and a 7 day gain of 3.13% set against a 90 day share price decline of 21.92%. The 1 year total shareholder return of 74.80% points to strong longer term momentum. If...

Lamb Weston Holdings (LW) is back in focus after reporting third quarter earnings and revenue above expectations, raising its 2026 net sales guidance, and outlining further cost actions in its international operations. See our latest analysis for Lamb Weston Holdings. The third quarter beat and raised 2026 net sales guidance come against a weaker share price backdrop, with a 30 day share price return of 12.73% and a 1 year total shareholder return decline of 26.94%, suggesting recent momentum...

Why WaFd (WAFD) Is On Investor Radar Today WaFd (WAFD) is drawing attention after recent share price moves, with the stock showing a small gain over the past week and month, while total return over the past year remains higher. See our latest analysis for WaFd. The recent 3.4% 30 day share price return, alongside a 32.2% 1 year total shareholder return, suggests recent momentum is modest while longer term holders have seen stronger gains. If WaFd has you looking beyond a single bank stock,...

ACM Research’s product rebrand and why it matters for investors ACM Research (ACMR) has reorganized its tools into the new ACM Planetary Family, grouping equipment into eight process based “planet” series that mirror semiconductor manufacturing steps across cleaning, deposition, plating, and advanced packaging. See our latest analysis for ACM Research. The rebrand arrives as ACM Research’s share price has been volatile, with a 9.86% 7 day share price return and recent 30 and 90 day declines...

Wondering whether NIKE at around US$44 per share is starting to look like value, or if the market is warning you to stay cautious. The stock has seen sharp recent moves, with a 14.1% decline over the last 7 days, 22.8% over 30 days, 30.4% year to date and 18.8% over the past year, on top of 61.8% and 65.2% declines over 3 and 5 years respectively. These price shifts have been occurring alongside ongoing discussions around NIKE's brand strength, product pipeline and competition in athletic...

Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia. See our latest analysis for Amylyx Pharmaceuticals. The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year...

Maximus stock overview Maximus (MMS) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past month and past 3 months. This has prompted closer scrutiny of its current valuation and fundamentals. See our latest analysis for Maximus. At a share price of $63.72, Maximus has seen a 30 day share price return of 18.32% and a 90 day share price return decline of 28.50%, while the 1 year total shareholder return sits at a decline...

Context for Agilysys (AGYS) investors Agilysys (AGYS) has drawn fresh attention after recent share price swings, with the stock showing mixed near term performance and a sharper decline over the past 3 months from a last close of $71.49. See our latest analysis for Agilysys. The recent pullback, including a 39% 3 month share price return decline and 38% year to date share price return decline from $71.49, contrasts with a 1 year total shareholder return of 6.4%, suggesting fading short term...

Moody's (MCO) is back in focus after quarterly earnings topped analyst expectations, with contributions from both its ratings and analytics divisions, along with higher full year earnings guidance and an increased quarterly dividend. See our latest analysis for Moody's. Despite a softer 30 day share price return of 5.91% and a 90 day share price return of 16.66%, Moody's 1 year total shareholder return of 12.47% and 3 year total shareholder return of 53.95% point to momentum that has built...

Noble recently participated in a project with Halliburton, ExxonMobil and the Wells Alliance Guyana team that achieved the first fully automated geological well placement with complete rig automation in offshore Guyana, integrating automated subsurface interpretation, well placement and real-time hydraulics. This milestone in Noble’s offshore operations highlights its role in advancing drilling automation, potentially reinforcing its positioning as a high-tech contractor in complex deepwater...

Fresh analyst commentary and Clorox (CLX) management remarks have pushed the stock back into focus as investors weigh cost inflation, trade down risks, currency headwinds, and a softer outlook for category growth. See our latest analysis for Clorox. At a share price of $104.89, Clorox has seen a 3.71% 1 day share price return and a 2.41% 7 day share price return. However, its 1 year total shareholder return of 21.39% and 5 year total shareholder return of 35.24% highlight fading longer term...

If you are looking at EPAM Systems and wondering whether the current share price reflects its true worth, the valuation picture is more nuanced than a quick glance at the chart suggests. The stock last closed at US$137.02, with a 0.6% move over the past week, a 6.1% decline over 30 days, and returns of 31.6% decline year to date and 5.5% decline over the past year, following even steeper 3-year and 5-year declines of 52.9% and 67.7% respectively. These moves have kept EPAM on the radar for...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

What AbbVie’s Recent Share Performance Signals for Investors AbbVie (ABBV) has recently seen a one-month return of about a 10% decline and a past three-month return of roughly a 7% decline, even as its one-year total return stands at about 14%. See our latest analysis for AbbVie. At a share price of US$206.69, AbbVie’s recent share price return has been weak over the past month and quarter, while its multi year total shareholder returns remain clearly positive. This suggests momentum has...